<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593281</url>
  </required_header>
  <id_info>
    <org_study_id>HZ2-05-06</org_study_id>
    <secondary_id>05-015-MI (Hospice #)</secondary_id>
    <nct_id>NCT00593281</nct_id>
  </id_info>
  <brief_title>INFUSE Morphine Study</brief_title>
  <acronym>INFUSE</acronym>
  <official_title>INcreased Flow Utilizing Subcutaneously Enabled Morphine (INFUSE-Morphine) With and Without Human Recombinant Hyaluronidase (HYLENEX) and Intravenously</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine&#xD;
      administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX)&#xD;
      and intravenously conducted in patients in a hospice care setting or through a palliative&#xD;
      care medicine setting. In this within-patient controlled study, each eligible study patient&#xD;
      receives a single injection by each of the three methods of morphine administration,&#xD;
      sequentially on three consecutive days, according to the order specified by a randomization&#xD;
      schedule.&#xD;
&#xD;
      Each of the three injections consists of 5 mg of morphine (1.0 mL of 5 mg/mL solution). The&#xD;
      HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be&#xD;
      blinded, the two SC injections will be double-blinded, using the same volume of normal saline&#xD;
      (0.9% sodium chloride) placebo (1.0 mL) as HYLENEX.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Determine the Tmax and other pharmacokinetic parameters of morphine injected subcutaneously with HYLENEX compared to without HYLENEX and injected intravenously</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the safety and tolerability of these three methods of injections of morphine</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>IV Morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC Morphine with Hylenex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SC Morphine with Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylenex</intervention_name>
    <description>Add Hylenex to SC injection of Morphine</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females at least 18 years of age who are patients of San Diego Hospice &amp;&#xD;
             Palliative Care or recruited through San Diego Hospice &amp; Palliative Care or the UCSD&#xD;
             Center for Pain and Palliative Medicine.&#xD;
&#xD;
          2. During the treatment days of the study, on opioid therapy other than morphine that is&#xD;
             equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.&#xD;
&#xD;
          3. Vital signs (BP, HR, RR) within normal range.&#xD;
&#xD;
          4. Adequate venous access in both upper extremities.&#xD;
&#xD;
          5. A negative pregnancy test (if female of child-bearing potential) within 7 days prior&#xD;
             to first injection.&#xD;
&#xD;
          6. Life expectancy ≥ ten days.&#xD;
&#xD;
          7. Decision-making capacity.&#xD;
&#xD;
          8. Signed, written IRB-approved informed consent. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or history of any toxicity to morphine.&#xD;
&#xD;
          2. Morphine within the 4 days prior to the first study medication injection or&#xD;
             anticipated to be receiving morphine during any of the treatment days in this study.&#xD;
&#xD;
          3. Any contraindication to morphine.&#xD;
&#xD;
          4. Known hypersensitivity to naloxone.&#xD;
&#xD;
          5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.&#xD;
&#xD;
          6. Known allergy to bee or vespid venom.&#xD;
&#xD;
          7. Contraindication to IV heparin lock or known hypersensitivity to heparin.&#xD;
&#xD;
          8. Edema, infection, or any other lower extremity or pelvic disorder that might affect&#xD;
             subcutaneous absorption from the thigh.&#xD;
&#xD;
          9. Hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
         10. Presence of any other medical condition that would present an unacceptable safety risk&#xD;
             to the patient.&#xD;
&#xD;
         11. Participation in a study of any investigational drug or device within 30 days of&#xD;
             enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Thomas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Hospice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark S Wallace, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Thornton Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Thornton Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Hospice and Palliative Care</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <last_update_submitted>January 11, 2008</last_update_submitted>
  <last_update_submitted_qc>January 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Richard Yocum, M.D.</name_title>
    <organization>Halozyme Inc.</organization>
  </responsible_party>
  <keyword>Hyaluronidase</keyword>
  <keyword>Hylenex</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>morphine</keyword>
  <keyword>absorption</keyword>
  <keyword>bioavailability</keyword>
  <keyword>PK study of morphine in patients with pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

